207 related articles for article (PubMed ID: 25870382)
21. Bisphosphonates and breast cancer prevention.
Chlebowski RT; Col N
Anticancer Agents Med Chem; 2012 Feb; 12(2):144-50. PubMed ID: 21864227
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.
Valachis A; Polyzos NP; Coleman RE; Gnant M; Eidtmann H; Brufsky AM; Aft R; Tevaarwerk AJ; Swenson K; Lind P; Mauri D
Oncologist; 2013; 18(4):353-61. PubMed ID: 23404816
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid for adjuvant use in patients with breast cancer.
Ressler S; Mlineritsch B; Greil R
Expert Rev Anticancer Ther; 2011 Mar; 11(3):333-49. PubMed ID: 21417849
[TBL] [Abstract][Full Text] [Related]
24. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
25. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients.
Solomayer EF; Gebauer G; Hirnle P; Janni W; Lück HJ; Becker S; Huober J; Krämer B; Wackwitz B; Wallwiener D; Fehm T
Ann Oncol; 2012 Sep; 23(9):2271-2277. PubMed ID: 22383680
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
Coleman RE
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
[TBL] [Abstract][Full Text] [Related]
27. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
Neville-Webbe Hl; Coleman RE
Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
He M; Fan W; Zhang X
J Hematol Oncol; 2013 Oct; 6(1):80. PubMed ID: 24283946
[TBL] [Abstract][Full Text] [Related]
30. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
31. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
33. Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
Ishikawa T; Akazawa K; Hasegawa Y; Tanino H; Horiguchi J; Miura D; Hayashi M; Kohno N
J Surg Res; 2017 Dec; 220():46-51. PubMed ID: 29180210
[TBL] [Abstract][Full Text] [Related]
34. Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer.
Bertoldo F; Tonini G; Vincenzi B; Santini D
Nat Rev Clin Oncol; 2009 Apr; 6(4):191-2. PubMed ID: 19333223
[No Abstract] [Full Text] [Related]
35. Breast cancer: Zoledronic acid--more than just a bone drug.
Mathew A; Brufsky A
Nat Rev Clin Oncol; 2014 Oct; 11(10):564-5. PubMed ID: 25200411
[TBL] [Abstract][Full Text] [Related]
36. [Effects of zoledronic acid in the treatment of breast cancer].
Chen J; Liu ZY; Zhao LJ
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
[No Abstract] [Full Text] [Related]
37. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
[TBL] [Abstract][Full Text] [Related]
38. The use of bisphosphonates in prostate cancer.
Khan MA
BJU Int; 2003 Jul; 92(1):152. PubMed ID: 12823405
[No Abstract] [Full Text] [Related]
39. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
[TBL] [Abstract][Full Text] [Related]
40. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
Brown JE; Cook RJ; Lipton A; Coleman RE
Clin Cancer Res; 2012 Nov; 18(22):6348-55. PubMed ID: 22952345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
